An interventional study of Ketone Monoester (KE) and Ketogenic diet in Nutrition and Obesity and Overweight, sponsored by University of Bath. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by University of Bath · Not applicable, Interventional, and Basic science
Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable.
Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet.
Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC \& NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors.
Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans.
The investigators will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. The investigators will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 69 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →University of Bath is the lead sponsor of 91 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Ketone Monoester (KE)
Behavioral: Ketogenic diet
25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].
Ketogenic diet (\<50 g carbohydrate per day)
Plasma proteome
Plasma proteome at week 4 adjusted for baseline values
Time frame: From baseline to week 4
Transcriptome of peripheral blood mononuclear cells
Transcriptome of peripheral blood mononuclear cells at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Transcriptome of adipose tissue
Transcriptome of subcutaneous abdominal adipose tissue at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Apolipoprotein B concentrations
Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.
Time frame: From baseline to week 4
Urinary albumin concentrations
Urinary albumin concentrations at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Fasting glucose concentrations
Plasma fasting glucose concentrations at week 4 adjusting for baseline values
Time frame: From baseline to week 4
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bath